Literature DB >> 4338668

Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin.

J J Brown, D L Davies, J B Ferriss, R Fraser, E Haywood, A F Lever, J I Robertson.   

Abstract

The effect of prolonged preoperative treatment with spironolactone has been studied in a series of 67 patients with hypertension, aldosterone excess, and low plasma renin. In the series as a whole a highly significant reduction in both systolic and diastolic pressures was achieved, with no evidence of escape from control during therapy lasting several years in some cases. The drug was equally effective in controlling blood pressure in patients with and without adrenocortical adenomata. Occasional unresponsive patients were encountered in both groups; pretreatment blood urea levels in these were significantly higher than in the responsive patients. The hypotensive effect of spironolactone usually predicted the subsequent response to adrenal surgery.Spironolactone in all cases corrected plasma electrolyte abnormalities; significant increases in total exchangeable (or total body) potassium and significant reductions in total exchangeable sodium, total body water, extracellular fluid, and plasma volumes were seen. Plasma urea rose during treatment and there was a slight fall in mean body weight. Significant increases in peripheral venous plasma renin and angiotensin II concentrations occurred during treatment.In two patients no increase in aldosterone secretion rate was found during treatment, although plasma aldosterone rose in three of four subjects studied.Severe side effects were rare; in only two of the 67 patients did the drug have to be stopped.In addition to its routine preoperative use, spironolactone can now be advised as long-term therapy in selected patients.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4338668      PMCID: PMC1788474          DOI: 10.1136/bmj.2.5816.729

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  42 in total

1.  Antihypertensive actions of diuretics. Comparative study of an aldosterone antagonist and a thiazide, alone and together.

Authors:  B M Winer; W F Lubbe; T Colton
Journal:  JAMA       Date:  1968-05-27       Impact factor: 56.272

2.  Renin, angiotensin, corticosteroids, and electrolyte balance in Addison's disease.

Authors:  J J Brown; R Fraser; A F Lever; J I Robertson; V H James; J McCusker; V Wynn
Journal:  Q J Med       Date:  1968-01

3.  Double isotope assay of aldosterone, corticosterone and cortisol in human peripheral plasma.

Authors:  R Fraser; V H James
Journal:  J Endocrinol       Date:  1968-01       Impact factor: 4.286

4.  The estimation of renin in human plasma.

Authors:  J J Brown; D L Davies; A F Lever; J I Robertson; M Tree
Journal:  Biochem J       Date:  1964-12       Impact factor: 3.857

5.  Plasma concentration of renin in a patient with Conn's syndrome with fibrinoid lesions of the renal arterioles: the effect of treatment with spironolactone.

Authors:  J J Brown; D L Davies; A F Lever; W S Peart; J I Robertson
Journal:  J Endocrinol       Date:  1965-10       Impact factor: 4.286

6.  Secondary aldosteronism and reduced plasma renin in hypertensive disease.

Authors:  J G Ledingham; J H Laragh; S C Sommers
Journal:  Trans Assoc Am Physicians       Date:  1967

7.  The development and performance of a prototype shadow-shield whole body monitor.

Authors:  K Boddy
Journal:  Phys Med Biol       Date:  1967-01       Impact factor: 3.609

8.  Primary aldosteronism with suppressed plasma renin activity due to bilateral nodular adrenocortical hyperplasia.

Authors:  F H Katz
Journal:  Ann Intern Med       Date:  1967-11       Impact factor: 25.391

9.  [Inhibition of plasmatic renin activity by potassium].

Authors:  R Veyrat; H R Brunner; E L Manning; A F Muller
Journal:  J Urol Nephrol (Paris)       Date:  1967 Apr-May

10.  Management of primary aldosteronism: evaluation of potassium and sodium balance, technic of adrenalectomy and operative results in 24 cases.

Authors:  W Silen; E G Biglieri; P Slaton; M Galante
Journal:  Ann Surg       Date:  1966-10       Impact factor: 12.969

View more
  22 in total

1.  [Plasma aldosterone and plasma renin activity in patients with essential and renal hypertension under acute stimulation with saline depletion and acute suppression with saline infusion].

Authors:  F Klumpp; D Klaus; R Lemke; J Zehner; P Zöfel
Journal:  Klin Wochenschr       Date:  1975-03-01

2.  Control of plasma aldosterone in a patient with Conn's syndrome before and during spironolactone medication.

Authors:  H Vetter; W Vetter
Journal:  Klin Wochenschr       Date:  1975-04-15

3.  Treating resistant hypertension with spironolactone.

Authors:  Kathleen H Berecek; Denise Kimbrough
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

Review 4.  Primary aldosteronism: a common cause of resistant hypertension.

Authors:  Gregory A Kline; Ally P H Prebtani; Alexander A Leung; Ernesto L Schiffrin
Journal:  CMAJ       Date:  2017-06-05       Impact factor: 8.262

5.  Suppression by the spironolactone metabolite canrenone of plasma testosterone in man.

Authors:  H C Erbler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

Review 6.  Diagnosis and management of primary aldosteronism.

Authors:  Malcolm H Wheeler; Dean A Harris
Journal:  World J Surg       Date:  2003-05-13       Impact factor: 3.352

7.  Periodic hypokalaemic paralysis, adrenal adenoma, and normal colonic transport of sodium and potassium.

Authors:  P Richards; M B Jones; W S Peart
Journal:  Gut       Date:  1973-06       Impact factor: 23.059

Review 8.  Effect of antihypertensive drugs on the renin-angiotensin system.

Authors:  C I Johnston
Journal:  Drugs       Date:  1976       Impact factor: 9.546

9.  Primary aldosteronism: difference in clinical presentation and long-term follow-up between adenoma and bilateral hyperplasia of the adrenal glands.

Authors:  T Jeck; B Weisser; T Mengden; L Erdmenger; S Grüne; W Vetter
Journal:  Clin Investig       Date:  1994-12

10.  Spironolactone in essential hypertension: evidence against its effect through mineralocorticoid antagonism.

Authors:  B I Hoffbrand; C J Edmonds; T Smith
Journal:  Br Med J       Date:  1976-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.